NEW YORK (GenomeWeb) – Epigenomics said today that it will receive a two-year, €2.8 million ($3.1 million) EU grant to fund clinical research to validate the company's lung cancer biomarkers.

The grant will be administered through the Industrial Leadership pillar of the EU's Horizon 2020 Research and Innovation Program for Small and Medium Enterprise Businesses.

The ultimate goal of Epigenomics' project is to develop a CE-marked product to detect lung cancer in blood plasma, the company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.

Sponsored by

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions.